NCT03786406 (EU-CAPTURE) is a clinical trial of No treatment given in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S.

Who is sponsoring NCT03786406?

NCT03786406 is sponsored by Novo Nordisk A/S.

What drugs are being tested in NCT03786406?

Interventions in NCT03786406: No treatment given.

What condition does NCT03786406 study?

NCT03786406 studies Diabetes Mellitus, Type 2.

Is NCT03786406 still recruiting?

NCT03786406 is currently completed. Last updated 22 June 2023.

Last reviewed 2023-06-22 · How we verify

NCT03786406: EU-CAPTURE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An International Survey of the Occurrence of Diseases That Affects the Heart and Blood Vessels Among People With Type 2 Diabetes

Completed Last updated 22 June 2023

What this trial tests

trial testing No treatment given in Diabetes Mellitus, Type 2 in 2,275 participants. Completed in 31 May 2019.

Timeline

3 December 2018

Primary endpoint
31 May 2019

31 May 2019

Quick facts

Lead sponsor	Novo Nordisk A/S
Status	Completed
Study type	OBSERVATIONAL
Enrollment	2,275
Start date	3 December 2018
Primary completion	31 May 2019
Estimated completion	31 May 2019
Sites	41 locations across France, Italy, Czechia

Drugs / interventions tested

No treatment given — full drug profile →

Conditions studied

Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →

Sponsor

Novo Nordisk A/S — full company profile →

Who can join

18 and older, any sex, with Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to register the occurrence of cardiovascular disease among type 2 diabetes (T2DM) patients across five selected countries in Europe. Participants will be asked to give information about their health. Participants will continue their normal way of life and will not get any medication other than what has been prescribed to them by their doctor. Participants' participation will be one day/one visit at study doctor. The study will last for about 3 months in total.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries.
Mosenzon O, Alguwaihes A, Leon JLA, Bayram F, et al · · 2021 · cited 167× · PMID 34315481 · DOI 10.1186/s12933-021-01344-0
The Prevalence of Cardiovascular Disease in Adults with Type 2 Diabetes in China: Results from the Cross-Sectional CAPTURE Study.
Hong T, Yan Z, Li L, Tang W, et al · · 2022 · cited 15× · PMID 35312971 · DOI 10.1007/s13300-022-01243-x
56<sup>th</sup> EASD Annual Meeting of the European Association for the Study of Diabetes : 21-25 September 2020.
· 2020 · cited 9× · PMID 32840677 · DOI 10.1007/s00125-020-05221-5
Contemporary (2019) prevalence of cardiovascular disease in adults with type 2 diabetes in Brazil: the cross-sectional CAPTURE study.
Vencio S, Vianna AGD, da Silva MACF, Precoma DB. · · 2022 · cited 5× · PMID 35012646 · DOI 10.1186/s13098-021-00775-9
Cardiovascular disease prevalence in adults with type 2 diabetes in Japan: results from the Japanese centers in the CAPTURE study.
Seino H, Onishi Y, Eguchi K, Nishijima K, et al · · 2023 · cited 3× · PMID 37090129 · DOI 10.1007/s13340-022-00612-y
A cross-sectional study on the prevalence of cardiovascular disease in elderly patients with long-term type 2 diabetes mellitus mainly attended in private clinics in Mexico. The CAPTURE study.
Arenas-León JL, Morales-Villegas EC, Cardona-Muñoz EG, Alcocer-Gamba MA, et al · · 2023 · PMID 38062472 · DOI 10.1186/s13098-023-01231-6
Use of diabetes medications in adults with T2D and CVD in Japan: secondary analysis of the CAPTURE study.
Onishi Y, Shirabe S, Eguchi K, Nishijima K, et al · · 2023 · PMID 37781463 · DOI 10.1007/s13340-023-00638-w
Contemporary (2019) prevalence of cardiovascular disease in adults with type 2 diabetes in Brazil: the cross-sectional CAPTURE study
Vencio S, Vianna AGD, Silva MACFd, Precoma DB. · · 2021 · DOI 10.21203/rs.3.rs-768461/v1

Verify or expand the search:

Other trials of No treatment given

Trials testing the same drug.

NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
NCT07358052 — Current Status of Cardiovascular Diseases in Chinese Overweight/ Obesity Population: An Epidemiological Study (COPE） · completed
NCT07201831 — A Multi-country, Cross-sectional Quantitative Study Exploring Awareness, Understanding, and Perceptions of the Relation · completed
NCT07154238 — Characteristics and Treatment Experiences of Individuals Using Injectable Semaglutide for Weight Management, a Cross-sec · enrolling by invitation
NCT07160829 — Focus on Levels of Awareness and Perceptions Regarding hsCRP in Identifying Systemic Inflammation in ASCVD, CKD and Hear · completed

Other recruiting trials for Diabetes Mellitus, Type 2

Currently open trials in the same condition.

NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 · Phase 2 · recruiting
NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) · Phase 1 · recruiting
NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting

Other Novo Nordisk A/S trials

Trials by the same sponsor.

NCT07357740 — A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes · Phase 2 · not yet recruiting
NCT07282613 — A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adoles · Phase 3 · not yet recruiting
NCT07357766 — A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight · Phase 3 · not yet recruiting
NCT07564414 — A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obe · Phase 3 · not yet recruiting
NCT07400107 — AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Exc · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03786406 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novo Nordisk A/S
Last refreshed: 22 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03786406.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing